{"id":58395,"date":"2023-11-10T22:01:53","date_gmt":"2023-11-10T21:01:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/"},"modified":"2023-11-10T22:01:53","modified_gmt":"2023-11-10T21:01:53","slug":"variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/","title":{"rendered":"Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis"},"content":{"rendered":"<div>\n<p>FRAMINGHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight\u2122 CNV Analysis &#8211; a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20231110772254\/en\/1942289\/5\/Variantyx_logo_%285%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231110772254\/en\/1942289\/21\/Variantyx_logo_%285%29.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20231110772254\/en\/1942289\/5\/Variantyx_logo_%285%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20231110772254\/en\/1942289\/22\/Variantyx_logo_%285%29.jpg\"><\/a><\/p>\n<p>\n\u201cIriSight\u2122 CNV Analysis provides the first true alternative to CMA,\u201d said Dr. Allan J. Fisher, FACOG, FACMG, Variantyx Medical Director. \u201cBecause the entire genome is sequenced, a broader range of chromosomal abnormalities are detected by the test including aneuploidy, unbalanced rearrangements, inversions, deletions\/duplications, copy number variants (CNVs), regions of homozygosity and possible uniparental disomy. Reflex options in cases with non-diagnostic outcomes offer the possibility of rapid and seamless, expanded whole genome analysis (WGS) of the already sequenced DNA that includes small sequence changes, mitochondrial variants, and short tandem repeat expansions.\u201d<\/p>\n<p>\nChromosomal microarray analysis (CMA) is recommended by both the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) for use in prenatal diagnosis. Variantyx\u2019s proprietary whole genome-based platform enables detection of a wider range of chromosomal abnormalities, not just matching but exceeding the capabilities of traditional CMA.<\/p>\n<p>\n<b>About Variantyx<\/b><\/p>\n<p>\nVariantyx is an award-winning, technology-driven precision medicine company providing disruptive solutions for the genetic disorders, reproductive health, and precision oncology markets. The proprietary whole genome analysis platforms developed by Variantyx allow clinicians and patients to better understand a person\u2019s genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.variantyx.com&amp;esheet=53808736&amp;newsitemid=20231110772254&amp;lan=en-US&amp;anchor=www.variantyx.com&amp;index=1&amp;md5=7b62051b71c9092b07c0b7df94018577\" rel=\"nofollow noopener\" shape=\"rect\">www.variantyx.com<\/a>.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nHaim Neerman<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x48;&#x61;&#x69;&#x6d;&#x2e;&#x6e;&#x65;&#x65;&#x72;&#x6d;&#x61;&#x6e;&#x40;&#x76;&#x61;&#x72;&#x69;&#x61;&#x6e;&#x74;&#x79;&#x78;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">Ha&#105;&#109;&#46;&#x6e;&#x65;&#x65;&#x72;&#x6d;an&#64;&#118;&#97;&#x72;&#x69;&#x61;&#x6e;&#x74;yx&#46;&#99;&#111;&#x6d;<\/a><br \/>(617) 209-2090<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>FRAMINGHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight\u2122 CNV Analysis &#8211; a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss. \u201cIriSight\u2122 CNV Analysis provides &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58395","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FRAMINGHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight\u2122 CNV Analysis &#8211; a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss. \u201cIriSight\u2122 CNV Analysis provides ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-10T21:01:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20231110772254\/en\/1942289\/21\/Variantyx_logo_%285%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis\",\"datePublished\":\"2023-11-10T21:01:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/\"},\"wordCount\":284,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231110772254\\\/en\\\/1942289\\\/21\\\/Variantyx_logo_%285%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/\",\"name\":\"Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231110772254\\\/en\\\/1942289\\\/21\\\/Variantyx_logo_%285%29.jpg\",\"datePublished\":\"2023-11-10T21:01:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231110772254\\\/en\\\/1942289\\\/21\\\/Variantyx_logo_%285%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20231110772254\\\/en\\\/1942289\\\/21\\\/Variantyx_logo_%285%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/","og_locale":"en_US","og_type":"article","og_title":"Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis - Pharma Trend","og_description":"FRAMINGHAM, Mass.&#8211;(BUSINESS WIRE)&#8211;Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight\u2122 CNV Analysis &#8211; a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss. \u201cIriSight\u2122 CNV Analysis provides ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/","og_site_name":"Pharma Trend","article_published_time":"2023-11-10T21:01:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20231110772254\/en\/1942289\/21\/Variantyx_logo_%285%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis","datePublished":"2023-11-10T21:01:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/"},"wordCount":284,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231110772254\/en\/1942289\/21\/Variantyx_logo_%285%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/","url":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/","name":"Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20231110772254\/en\/1942289\/21\/Variantyx_logo_%285%29.jpg","datePublished":"2023-11-10T21:01:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20231110772254\/en\/1942289\/21\/Variantyx_logo_%285%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20231110772254\/en\/1942289\/21\/Variantyx_logo_%285%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/variantyx-expands-its-reproductive-health-offerings-with-launch-of-a-direct-replacement-for-chromosomal-microarray-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Variantyx Expands Its Reproductive Health Offerings with Launch of a Direct Replacement for Chromosomal Microarray Analysis"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58395"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58395\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}